A grading system based on severity of infection to predict mortality in allogeneic stem cell transplant recipients

被引:12
作者
Cordonnier, Catherine
Maury, Sebastien
Ribaud, Patricia
Kuentz, Mathieu
Bassompierre, Francois
Gluckman, Eliane
Chevret, Sylvie
机构
[1] Hop Henri Mondor, AH HP, Dept Hematol, Serv Hematol Clin, F-94000 Creteil, France
[2] Univ Paris 12, F-94010 Creteil, France
[3] Hop St Louis, Unite Greffe Moelle, St Louis, France
[4] Hop St Louis, Delegat Reg Rech Clin, St Louis, France
[5] INSERM, U717, F-75654 Paris 13, France
关键词
hematopoeitic stem cell transplantation; infection; mortality;
D O I
10.1097/01.tp.0000225762.54757.f7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is, until now, no prognostic grading system for infections occurring in allogeneic stem cell transplant (SCT) recipients. The aim of this study was to determine the prognostic value of a grading system of infectious complications in predicting death. Methods. For the purposes of a prospective allogeneic SCT trial, we classified severity of infections in 3 grades according to expected rates of mortality (>= 60% for grade 3). We prospectively recorded the type and time of occurrence of 440 infectious events in 190 consecutive patients until 6 months after transplant. We used multivariate Cox models with time-dependent covariates to analyze the relationship between the grade of severity of each infectious episode and mortality due or not due to infection, adjusting for possible confounders. Results. Only patients with grade 3 infections had a significantly increased risk of death (P <.0001). The risk was not modified when the occurrence of acute graft-versus-host disease or the dose of IVIg administered were considered. Occurrence of a grade 1 and 2 infection had no additional influence. Conclusion. Our grading system identifies the most medically important, life-threatening infections and allow high-risk patients to be identified. We suggest grade 3 infections should be given priority in the evaluation of anti-infectious strategies.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 43 条
[1]   Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants [J].
Abdel-Mageed, A ;
Graham-Pole, J ;
Del Rosario, MLU ;
Longmate, J ;
Ochoa, S ;
Amylon, M ;
Elfenbein, GJ ;
Janiec, J ;
Jansen, J ;
Lazarus, HM .
BONE MARROW TRANSPLANTATION, 1999, 23 (09) :929-932
[2]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]   Severity of illness scores: Are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study [J].
Blot, F ;
Cordonnier, C ;
Buzin, A ;
Nitenberg, G ;
Schlemmer, B ;
Bastuji-Garin, S .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2125-2131
[4]  
BOWDEN RA, 1998, TRANSPLANT INFECT
[5]   Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals [J].
BrunBuisson, C ;
Doyon, F ;
Carlet, J ;
Bedock, B ;
Annonay, CH ;
Valente, E ;
Lescale, O ;
Misset, B ;
Charbonneau, P ;
Vergnaud, M ;
Cohen, R ;
Coloignier, M ;
Frances, JL ;
Combes, A ;
Duval, O ;
Dellamonica, P ;
Descamps, JM ;
Domart, Y ;
Galiacy, JL ;
Gouin, F ;
Guivarch, G ;
Hennequin, C ;
Krajevitch, A ;
Delmas, P ;
Holzapfel, L ;
Lepeu, G ;
Loirat, P ;
Thaler, F ;
Knani, L ;
Mercier, JC ;
Mouton, Y ;
Libbrecht, E ;
Offenstadt, G ;
Pinaud, M ;
Pinsart, M ;
Girou, E ;
Portier, H ;
Grappin, M ;
Rebeix, MT ;
Regnier, B ;
Gachot, B ;
Ricome, JL ;
Sollet, JP ;
Mentec, H ;
Tempelhoff, G ;
Beuret, P ;
Lepoutre, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) :617-624
[6]   Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy [J].
Cometta, A ;
Kern, WV ;
De Bock, R ;
Paesmans, M ;
Vandenbergh, M ;
Crokaert, F ;
Engelhard, D ;
Marchetti, O ;
Akan, H ;
Skoutelis, A ;
Korten, V ;
Vandercam, M ;
Gaya, H ;
Padmos, A ;
Klastersky, J ;
Zinner, S ;
Glauser, MP ;
Calandra, T ;
Viscoli, C .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :382-389
[7]   Epidemiology and risk factors for gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy [J].
Cordonnier, C ;
Buzyn, A ;
Leverger, G ;
Herbrecht, R ;
Hunault, M ;
Leclercq, R ;
Bastuji-Garin, S .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :149-158
[8]   Should immunoglobulin therapy be used in allogeneic stem-cell transplantation?: A randomized, double-blind, dose effect, placebo-controlled, multicenter trial [J].
Cordonnier, C ;
Chevret, S ;
Legrand, M ;
Rafi, H ;
Dhédin, N ;
Lehmann, B ;
Bassompierre, F ;
Gluckman, E .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (01) :8-18
[9]   Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study [J].
Cordonnier, C ;
Herbrecht, R ;
Pico, JL ;
Gardembas, M ;
Delmer, A ;
Delain, M ;
Moreau, P ;
Ladeb, S ;
Nalet, V ;
Rollin, C ;
Gres, JJ .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (01) :41-51
[10]  
Cunningham I, 1992, Semin Respir Infect, V7, P132